



## Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of \$345 Million

October 10, 2025

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 8,048,782 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,097,561 additional shares, at a public offering price per share of \$41.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 365,853 shares of its common stock at a public offering price of \$40.99999 per pre-funded warrant. The pre-funded warrants have an exercise price of \$0.00001 per share and are exercisable immediately. The aggregate gross proceeds to Apogee from the offering were approximately \$345 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Jefferies, BofA Securities, Guggenheim Securities and TD Cowen acted as joint book-running managers for the offering. BTIG acted as passive bookrunner for the offering.

An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on August 12, 2024. This offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC, are available on the SEC's website at [www.sec.gov](http://www.sec.gov) and may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com); BofA Securities, NC1-0220-02-24, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at: [dg.prospectus\\_requests@bofa.com](mailto:dg.prospectus_requests@bofa.com); Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [GSEquityProspectusDelivery@guggenheimpartners.com](mailto:GSEquityProspectusDelivery@guggenheimpartners.com); or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [TDManualrequest@broadridge.com](mailto:TDManualrequest@broadridge.com).

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### About Apogee

Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD), and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class profiles through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care.

### Investor Contact:

Noel Kurdi  
VP, Investor Relations  
Apogee Therapeutics, Inc.  
[Noel.Kurdi@apogeetherapeutics.com](mailto:Noel.Kurdi@apogeetherapeutics.com)

### Media Contact:

Dan Budwick  
1AB Media  
[dan@1abmedia.com](mailto:dan@1abmedia.com)